Product category:
HTS and combinatorial chemistry equipment
News Release from: Cellomics Europe | Subject: CellSelect BioApplication access plan
Edited by the Laboratorytalk Editorial
Team on 20 January 2004
More flexibility in high content
screening
Access plan provides scientists performing high content screening with a more flexible and economical way to purchase and utilise applications
Cellomics has announced its CellSelect BioApplication access plan For scientists performing high content screening (HCS) "the CellSelect access plan provides customers with a more flexible and economical way to purchase and utilise our 17 powerful BioApplications" according to Sarah Burroughs Tencza, product manager at Cellomics
This article was originally published on Laboratorytalk on 11 Oct 2001 at 8.00am (UK)
Related stories
Automation for cell-based drug discovery
The ArrayScan HCS system from Cellomics is a proprietary drug discovery instrument that performs automated measurement and analysis of spatial and temporal events in cells
Hallmark indicators of drug toxicity
The multiparameter Cytotoxicity 1 assay is the latest in Cellomics's series of HitKits, to quantify multiple hallmark indicators of drug toxicity in cells
"Cellomics has the largest portfolio of BioApplications available, and the CellSelect access plan will increase the productivity of our HCS customers so that HCS assays can be used in a broader range of drug discovery and therapeutic programs".
CellSelect BioApplication packages enable scientists to purchase more image analysis algorithms for their ArrayScan HCS readers and vHCS Discovery Toolbox, enhancing the flexibility of the system.
The four different access plan levels, bronze, silver, gold, and platinum, provide progressive discounts on BioApplications as well as other benefits and services including new BioApplications, training, reagents, and enhanced customer support.
CellSelect will further expand the role of HCS in drug discovery," said Tencza.
By utilising this large portfolio of easy-to-use, and in some cases patented, algorithms, drug discovery companies can extend the benefits of HCS into all of their therapeutic areas for target identification and lead optimisation, through the process to toxicology testing.
"Our customers can now realise the full potential of HCS through our many BioApplications and easily see the value in accessing our portfolio of current and future releases.".
• Cellomics Europe: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
